Analyst Reco. Cara Therapeutics, Inc.

Equities

CARA

US1407551092

Market Closed - Nasdaq Other stock markets 21:00:00 18/06/2024 BST			5-day change	1st Jan Change
0.2426 ^USD	-4.71%		-64.30%	-67.35%

06-18	Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program	MT
06-13	Needham Downgrades Cara Therapeutics to Hold From Buy	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Needham Downgrades Cara Therapeutics to Hold From Buy	06-13	MT
HC Wainwright Downgrades Cara Therapeutics to Neutral From Buy	06-13	MT
Stifel Downgrades Cara Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $6	06-13	MT
Canaccord Genuity Downgrades Cara Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10	06-13	MT
Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	03-06	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $2.50 From $7, Keeps Buy Rating	12-19	MT
Needham Adjusts Price Target on Cara Therapeutics to $6 From $22, Maintains Buy Rating	12-18	MT
Piper Sandler Downgrades Cara Therapeutics to Neutral From Overweight, Cuts Price Target to $1 From $12	11-14	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $7 From $15, Keeps Buy Rating	19/10/23	MT
HC Wainwright Lowers Price Target on Cara Therapeutics to $15 From $20, Maintains Buy Rating	16/05/23	MT
BofA Securities Adjusts Price Target on Cara Therapeutics to $4 From $6, Maintains Underperform Rating	16/05/23	MT
BofA Securities Downgrades Cara Therapeutics to Underperform From Neutral, Cuts PT to $6 From $13 on Lower Peak Sales Forecast of Drug	08/03/23	MT
BofA Downgrades Cara Therapeutics to Underperform From Neutral, Adjusts Price Target to $6 From $13	08/03/23	MT
Canaccord Genuity Adjusts Price Target on Cara Therapeutics to $25 From $29, Maintains Buy Rating	07/03/23	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $20 From $25, Keeps Buy Rating	07/03/23	MT
Piper Sandler Adjusts Price Target on Cara Therapeutics to $13 From $25, Keeps Overweight Rating	07/03/23	MT
JPMorgan Adjusts Price Target on Cara Therapeutics to $16 From $19, Maintains Overweight Rating	07/03/23	MT
Needham Cuts Price Target on Cara Therapeutics to $22 From $26, Maintains Buy Rating	07/03/23	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $25 From $30, Maintains Buy Rating	14/02/23	MT
Canaccord Genuity Adjusts Cara Therapeutics' Price Target to $29 from $33, Keeps Buy Rating	14/03/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cara Therapeutics, Inc.

Equities

CARA

US1407551092

Analyst Reco.

Filters